Moderna vs Pfizer: why the prices moved differently

• ▲

  Nasdaq-100 inclusion to bring index-fund demand Moderna will join the Nasdaq-100 on October 9, replacing Warner Bros. Discovery. Index funds tracking the index, which has over $800 billion in assets, must buy the stock, creating a fresh wave of demand. This is a new event that can lift the share price in the near term.

  It is a new, concrete catalyst that directly affects demand for MRNA shares.

• ▲

  Cancer vaccine moves toward commercialization with Tempus deal Tempus will help Moderna and Merck collect tumor samples and handle the complex sequencing needed to make the personalized cancer vaccine intismeran autogene. This supports the path to selling the treatment, a potential multi-billion-dollar product. It is a new step that boosts confidence in future revenue.

  It is a new development that advances the cancer vaccine toward market, supporting the growth story.

• ▼

  Citi downgrade warns valuation is too high Citi downgraded Moderna to sell, saying the stock price cannot be justified after the cancer vaccine win. The analyst argues the market is pricing in far more sales and profit than Moderna is likely to deliver. This is a new warning that could pull the stock down as investors rethink the rally.

  It is a new analyst action that directly challenges the stock's valuation and can pressure the price.

• ▼

  Patent lawsuit over mRNA technology moves forward A Delaware judge refused to dismiss Monsanto's patent infringement lawsuit against Moderna over its COVID-19 vaccine. The case will now proceed, creating legal uncertainty and potential financial liability. This is a new legal setback that could weigh on the stock.

  It is a new legal development that introduces risk and uncertainty for MRNA.

Based on 14 stories →

• ▲

  FDA panel backs mRNA flu shot An FDA advisory panel voted unanimously that Moderna's mRNA flu shot, mFlusiva, is safe and effective for adults 50 and older. This clears a key regulatory hurdle and opens a second big market beyond COVID, supporting the stock.

  This is a new regulatory milestone that expands Moderna's commercial opportunity.

• ▲

  Bird flu vaccine enters Phase 3 Moderna started a late-stage trial of its mRNA bird flu vaccine with backing from an international pandemic group. It shows the mRNA platform can target new infectious diseases, adding another potential long-term growth driver.

  This is a new pipeline advancement that broadens the platform's application.

• ▲

  Cancer vaccine Phase 3 success confirmed Moderna and Merck's personalized mRNA cancer vaccine met its main goal in a large melanoma trial, cutting recurrence risk. This is the first late-stage win for an mRNA cancer therapy, opening a potential multi-billion-dollar market and driving the stock sharply higher.

  This is the core new event that re-rates Moderna's growth story.

• ▲

  Stock extends rally on cancer data MRNA jumped 6% to $154, extending a 137% one-month rally, as investors continued to bet on the melanoma vaccine data. No new company news drove the move, but the market is rewarding Moderna's specific cancer asset over rivals.

  This shows the market's ongoing positive reaction to the cancer vaccine news.

Based on 6 stories →

• ▲

  FDA approves updated COVID and first mRNA flu shots Moderna won FDA approval for updated Spikevax and mNEXSPIKE COVID vaccines and mFlusiva, the first mRNA flu shot for adults 50+. This expands its sellable respiratory portfolio, though annual uptake and pricing will decide how much it really adds.

  New regulatory approvals directly expand Moderna's product lineup and revenue potential.

• ▲

  GSK's mRNA flu vaccine advance validates platform GSK said it will move its mRNA flu vaccine into Phase III after positive Phase II results. Investors saw this as proof that mRNA works for flu, not as a threat, and Moderna shares rose nearly 10% on the news.

  A rival's progress independently validates the mRNA platform Moderna is built on.

• ▲

  August surge and $2B raise show investor conviction Moderna ended August up 156%, the top S&P 500 performer, after the melanoma trial win. It also raised $2 billion in convertible notes for its cancer vaccine business, and hedge fund holdings rose 10% to $1.5 billion.

  Confirms the cancer breakthrough is translating into real capital and sustained investor backing.

Based on 6 stories →

• ▲

  First mRNA cancer vaccine clears Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a 1,137-patient melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the single biggest new event of the period and the core reason MRNA moved.

• ▲

  Analyst upgrades and huge sales forecasts William Blair upgraded Moderna to Outperform and Wolfe Research to peer perform, while forecasts for intismeran peak sales range from $1.4 billion (Leerink) to $16.8 billion (Morningstar) by 2035. These signal professional investors see the cancer win as a durable business driver, not just a one-day pop.

  Upgrades and forecasts show whether the cancer win is treated as lasting value, which drives the stock beyond the initial spike.

• ▼

  $2.6B convertible note raise dilutes and pressures stock Moderna plans to raise $2.6 billion via convertible notes due 2032 for its cancer vaccine business and debt repayment. Convertible notes can dilute existing shareholders if converted, and the stock fell about 5% premarket and 4% intraday on the news, a real counterweight to the rally.

  This is the main new negative force this period and explains why MRNA fell for three straight sessions.

• ◆

  BioNTech's trial failure cuts both ways BioNTech halted a Phase 2 mRNA cancer vaccine trial in colorectal cancer for futility, sending its shares down 10% and dragging Moderna lower on negative read-across. But the failure also highlights Moderna's melanoma success, where it targeted a 'hot' tumor with Keytruda, strengthening its competitive position.

  This is a new event that both pressures MRNA via sector sentiment and supports its relative advantage.

Based on 23 stories →

• ▲

  First mRNA cancer vaccine wins Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a large melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the core new event that explains the period's massive move and changes Moderna's long-term growth story.

• ▲

  Analysts upgrade and raise sales forecasts BofA upgraded Moderna to Neutral with a $170 target and lifted its peak sales estimate for intismeran to $54 billion, while William Blair moved to Outperform. These upgrades signal that professional investors see the cancer win as a real, durable business driver, not just a one-day pop.

  Analyst upgrades and raised forecasts show the market is repricing Moderna's future revenue, which supports the stock beyond the initial spike.

• ▼

  Sharp pullback after record surge After the record 177% jump, MRNA fell about 20-23% the next day as some investors took profits. Such a violent swing shows the stock is now very volatile and that not everyone believes the rally is justified, which can scare off cautious investors.

  The pullback is a real counterweight to the positive news and shows the risk that the stock has run far ahead of fundamentals.

• ◆

  Valuation gap and short-seller pain Even after the surge, the average analyst price target is only about $44, far below the last close near $133, suggesting the stock may be overvalued. Short sellers lost about $5.5 billion, which can fuel further sharp moves in either direction as positions unwind.

  This highlights the tension between the exciting science and the stock's stretched valuation, a key risk for new investors.

Based on 20 stories →

• ▲

  FDA approves first mRNA flu vaccine Moderna won FDA approval for mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. This is a major milestone: a new product to sell and proof its mRNA technology works beyond COVID, which can lift the stock.

  This is the biggest new event, directly adding a new product and validating the platform.

• ▼

  Norovirus vaccine fails interim analysis Moderna's norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, and the company will enroll more patients. This is a pipeline setback that can weigh on the stock by raising doubts about other vaccine programs.

  This is a new negative event that offsets the flu approval and affects pipeline sentiment.

• ▲

  Ebola vaccine trial starts Moderna began a Phase 1 trial of an Ebola vaccine for a strain with no approved shot, backed by up to $50 million from CEPI. It shows the mRNA platform can target new diseases, supporting the long-term growth story even if revenue is years away.

  This is a new pipeline milestone that broadens the platform's potential beyond COVID and flu.

• ▼

  Arbutus settlement payment Arbutus received a $178 million payment from Moderna as part of a $950 million patent settlement. This is cash leaving Moderna and a reminder that legal costs from past patent disputes continue to weigh on finances.

  This is a new cash outflow event that affects Moderna's financial position.

Based on 6 stories →

• ▲

  Q2 earnings beat and outlook reaffirmed Moderna beat second-quarter revenue and loss estimates and reaffirmed its full-year growth target. This shows the business is performing better than expected, which supports the stock price by reducing fears about cash burn and future funding needs.

  This is the main new financial event of the period and directly affects investor confidence in MRNA.

• ▲

  FDA decision on mRNA-1010 flu vaccine due August 5 An FDA ruling on Moderna's standalone flu shot is expected within days. Approval would give Moderna a fifth commercial product and help rebuild its respiratory vaccine business, potentially lifting the stock if the decision is positive.

  This is a near-term regulatory catalyst that could significantly change MRNA's product lineup and revenue outlook.

• ▼

  Norovirus vaccine trial misses early metric Moderna's norovirus vaccine trial missed an early goal, disclosed alongside earnings. This is a setback for a pipeline candidate and may dampen enthusiasm about the company's broader vaccine prospects, weighing on the stock.

  This is a new negative development that tempers the positive earnings news and highlights pipeline risk.

• ▲

  Strong Q1 revenue growth and AI ranking Moderna's Q1 revenue surged 260% year-over-year, the fastest among therapeutics stocks, and it ranked third in an investor survey of AI integration. These reinforce the growth narrative and positive sentiment, though the AI angle is not a major valuation driver.

  This provides context on Moderna's recent financial momentum and investor perception, supporting the bull case.

Based on 7 stories →

• ▲

  Analyst upgrade and Cramer's bullish turn Piper Sandler raised its price target, and Jim Cramer said Moderna is investable again, citing the pipeline shift into cancer, rare diseases, and a new flu shot. These endorsements drew new buyers, pushing the stock up sharply.

  New analyst and media endorsements directly lifted investor sentiment and the stock price.

• ▲

  Science Day fuels mRNA expansion hopes Moderna's Science Day showcased plans to move beyond vaccines into cancer therapies, autoimmune treatments, and an in vivo CAR-T candidate. Investors saw a broader future beyond COVID, driving the stock to a 52-week high and adding billions in market value.

  The Science Day event was a major catalyst that expanded the growth story and attracted investors.

• ▼

  Vaccine skepticism resurfaces Renewed political focus on vaccine skepticism sent Moderna shares down nearly 11% in one day. This shows that political and public-health headwinds can still hit the stock hard, even as the pipeline improves.

  This is a new negative development that highlights a real risk to Moderna's core vaccine business.

• ▼

  Patent settlement cash outflow Moderna paid $178 million to Arbutus as part of a patent settlement. While the amount is smaller than earlier settlements, it is still cash out the door and a reminder that legal costs continue to weigh on finances.

  This new payment is a concrete financial hit and shows ongoing litigation costs.

Based on 6 stories →

• ▲

  Science Day showcases pipeline beyond COVID Moderna's Science Day highlighted progress in cancer, autoimmune, and next-generation mRNA treatments, including its first cancer prevention program and a multiple sclerosis therapy. This expands the company's potential beyond COVID vaccines, giving investors new reasons to believe in future growth and pushing the stock up.

  This is the main new event of the period and directly explains the stock's surge.

• ▲

  FDA panel backs flu vaccine, approval decision in August An FDA advisory panel voted 9-0 in favor of Moderna's mRNA flu vaccine for adults 50 and older, making final approval by August 5 much more likely. A new revenue stream would reduce reliance on COVID vaccines, boosting investor optimism and the stock price.

  This is a new regulatory milestone that de-risks a key product and supports the stock's rise.

• ▲

  Strong Q1 revenue growth beats expectations Moderna's first-quarter revenue jumped 260% year over year to $389 million, beating analyst estimates by 55.8%. This shows the business is growing faster than expected, which supports the stock price even though the company still posted a loss.

  This new earnings data provides fundamental support for the stock's recent gains.

• ◆

  Analysts still cautious despite strong run Even after the stock surged nearly 42% in a month, Quant Ratings, Seeking Alpha analysts, and Wall Street analysts maintain a Hold rating. This suggests that while the pipeline is promising, significant risks remain, which could limit further upside or lead to pullbacks.

  This provides a fair counterweight to the positive news and explains why the stock isn't rated a buy.

Based on 7 stories →

• ▲

  FDA panel unanimously backs Moderna's flu vaccine An FDA advisory committee voted 9-0 that Moderna's mRNA flu vaccine is safe and effective for adults 50 and older. This key endorsement makes approval by the August 5 deadline much more likely, opening a new revenue stream and boosting investor confidence.

  This is the main new event that directly lifts MRNA's price by de-risking a major product approval.

• ▲

  Moderna plans three new vaccine launches by 2028 Moderna said it will launch a combined flu-COVID shot, a seasonal flu vaccine, and a norovirus vaccine between 2027 and 2028. It also expects important trial results this year for a personalized cancer therapy and a rare disease treatment, which could lead to its first oncology and rare disease products.

  This new pipeline update shows future growth beyond COVID vaccines, supporting a higher stock price.

• ▼

  Moderna to pay $2.25 billion in patent settlement Moderna agreed to a $2.25 billion global settlement with Roivant Sciences to resolve patent-infringement litigation. This is a large cash outflow that reduces Moderna's financial flexibility and is a real cost, even though it removes a legal cloud.

  This new settlement is a significant negative financial event that weighs on MRNA's price.

Based on 7 stories →

• ▼

  Overseas revenue sharing caps pricing upside Pfizer must share part of any extra overseas drug revenue with the U.S. government under its most-favored-nation pricing deal, running through early 2029. This limits how much Pfizer can profit from higher prices abroad, a direct drag on future earnings.

  This is a new pricing rule that directly reduces Pfizer's overseas profit potential.

• ▲

  New drugs and cost cuts offset COVID decline Pfizer said new and acquired medicines grew from $500 million in 2023 to $4 billion internationally, with $3.2 billion in Q2 alone. It also cut costs and tripled sales-force productivity, helping replace falling COVID revenue and supporting the stock.

  This shows the core growth strategy working, which is key to the investment case.

• ▲

  Pipeline successes in eczema and vitiligo Pfizer's eczema drug tilrekimig met its Phase 2 goal with strong skin clearance, and LITFULO hit Phase 3 targets in vitiligo, with regulatory filings planned. These add new potential growth drivers beyond COVID and cancer.

  Positive trial results are new evidence that Pfizer's pipeline can deliver future revenue.

• ▲

  Oncology expands with TUKYSA approval and Padcev growth The FDA approved TUKYSA as a chemotherapy-free frontline maintenance option for HER2-positive breast cancer, and Padcev won European backing for bladder cancer. Oncology sales are expected to rise, offsetting declines in older drugs.

  These approvals and expected sales growth strengthen Pfizer's cancer business, a key growth engine.

Based on 15 stories →

• ▼

  Moderna's new approvals add COVID and flu competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for older adults. That means more rivals fighting for the same pharmacy shelf space and patient visits, which can pressure Pfizer's COVID vaccine sales and slow its push into flu.

  New competitive threat directly affecting Pfizer's respiratory vaccine revenue.

• ▲

  Oncology sales and pipeline strengthen Pfizer's cancer business grew 3% to $4.17 billion last quarter, led by Padcev, up 23%, after an FDA approval expanded its patient pool. Pfizer is also testing a promising new cancer drug and aims for eight or more blockbuster cancer medicines by 2030, giving investors a concrete growth engine.

  Shows a real, current revenue driver offsetting declines elsewhere.

• ▲

  Obesity and oncology pipeline is the growth story Pfizer now has 95 pipeline programs, with the biggest bets in obesity and cancer. Its monthly obesity shot berobenatide could launch around 2028 in a market expected to reach $114 billion. Progress here is what investors are counting on to replace lost COVID and patent revenue.

  Explains the long-term growth thesis that supports the stock.

• ▼

  Dividend and 2026 guidance under pressure Pfizer's 6.19% dividend is only thinly covered by free cash flow, with $60.5 billion of debt competing for the same cash. Management also guided 2026 revenue and earnings below 2025 levels as COVID sales collapse and patents expire. That combination limits financial flexibility and keeps a lid on the stock.

  Highlights the main financial risk weighing on Pfizer's valuation.

Based on 6 stories →

• ▲

  Obesity drug berobenatide targets 2028 approval Pfizer's lead obesity drug berobenatide is advancing in late-stage trials, with a potential 2028 approval. It aims to compete in a market expected to reach $114 billion by 2030. This offers a major new growth path as older drugs lose patent protection, supporting the stock.

  This is a new pipeline update that could drive future revenue growth, directly answering what's moving PFE.

• ▲

  Eliquis strength lifts partner Bristol Myers' outlook Bristol Myers raised its 2026 revenue guidance after Eliquis sales grew 19% in the first half. Pfizer co-markets Eliquis, so it shares in these profits. Stronger-than-expected sales mean more cash for Pfizer, helping offset declines elsewhere and supporting the stock.

  This new update shows a key Pfizer product performing well, directly boosting Pfizer's revenue outlook.

• ▲

  FDA approves updated COVID vaccine, EMA reviews Lyme shot The FDA approved Pfizer's XFG-adapted COVID vaccine for high-risk groups, allowing immediate U.S. distribution. Separately, the EMA validated Pfizer's Lyme disease vaccine application. These regulatory wins support near-term COVID sales and add a potential new vaccine revenue stream.

  These are new regulatory milestones that directly affect Pfizer's product sales and pipeline prospects.

• ▼

  Drug pricing pressure and patent cliff concerns linger The Trump administration is expected to announce a drug pricing agreement with mid-sized biotech firms, and Pfizer was among major companies urged to cut U.S. prices. Meanwhile, Pfizer's total growth was only 1% and it posted a net loss, with major drugs facing patent expirations through 2030.

  This highlights ongoing regulatory and competitive pressures that could weigh on Pfizer's future revenue and stock.

Based on 8 stories →

• ▲

  Pfizer raises 2026 revenue guidance on non-COVID drugs Pfizer beat Q2 estimates and raised its 2026 revenue forecast by $500 million to $60.5–$62.5 billion, driven by strong non-COVID products. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

  This is the main new positive event of the period and directly boosts investor confidence in Pfizer's growth.

• ▲

  Pfizer expands cost-cutting, expects $2.5 billion extra savings Pfizer announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, raising total net savings to about $9.7 billion. Lower costs improve future profits and cash flow, which supports the stock.

  This is a new financial development that improves Pfizer's profitability outlook and helps fund its dividend.

• ▲

  EMA validates Pfizer-Valneva Lyme disease vaccine application The European Medicines Agency validated the marketing application for Pfizer and Valneva's Lyme disease vaccine candidate, based on Phase 3 efficacy above 70%. If approved, it could be the first such vaccine in Europe, adding a new revenue stream and supporting the stock.

  This is a new regulatory milestone that advances a potential new vaccine product for Pfizer.

• ▼

  Arbutus patent lawsuits over lipid nanoparticle technology persist Arbutus filed three international patent infringement lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in COVID vaccines. This adds legal costs and uncertainty, weighing on the stock.

  This is a new legal development that creates ongoing risk and potential financial liability for Pfizer.

Based on 7 stories →

• ▲

  Q2 earnings beat and raised revenue guidance Pfizer beat profit estimates and raised the low end of its 2026 revenue forecast to $60.5–$62.5 billion, driven by strong non-COVID drugs like Eliquis, Padcev, and Vyndaqel. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

  This is the period's biggest positive catalyst, directly boosting investor confidence in Pfizer's financial outlook.

• ▲

  Pipeline wins: LITFULO vitiligo and berobenatide obesity data Pfizer reported positive Phase 3 results for LITFULO in vitiligo and Phase 2b data showing its weight-loss drug berobenatide achieved 16% weight loss. These advance Pfizer's pipeline into new markets, offering future growth to replace aging drugs.

  These pipeline successes are new and show Pfizer's ability to develop new revenue sources, which is key to offsetting the patent cliff.

• ▲

  FDA priority review for TALZENNA+XTANDI and EU COVID vaccine authorization The FDA granted priority review to Pfizer's TALZENNA+XTANDI for earlier-stage prostate cancer, and the EU authorized Pfizer's updated COVID-19 vaccine. These regulatory milestones expand market opportunities and support sales in the near term.

  Regulatory progress is a new positive development that can lead to additional revenue streams and shows Pfizer's ability to navigate approvals.

• ▼

  Dividend strain and patent cliff concerns persist Pfizer's dividend payout exceeded 130% of earnings, raising concerns about financial strain as major drugs like Ibrance and Eliquis face patent expirations in 2027–2028. Management reaffirmed the dividend, but the high yield reflects investor worries about future cash flows.

  This is a key counterweight to the positive news, highlighting the financial challenges that could pressure the stock if not addressed.

Based on 12 stories →

• ▲

  FDA approvals expand Ibrance and Padcev labels The FDA approved Ibrance for a new breast cancer type and Padcev with Keytruda for bladder cancer. These label expansions grow Pfizer's oncology sales and help replace falling COVID revenue, supporting the stock.

  New regulatory wins directly boost Pfizer's revenue outlook and investor confidence.

• ▲

  Competitor's ATTR-CM trial failure lifts Vyndamax AstraZeneca's ATTR-CM drug failed a late-stage trial, removing a potential rival to Pfizer's Vyndamax. This reduces competition for a $5.4 billion franchise, making Pfizer's rare-disease business more durable.

  Less competition protects a key Pfizer product's sales and pricing power.

• ▲

  Voluntary drug-pricing deal with Trump administration Pfizer signed a most-favored-nation pricing agreement, offering discounts on 30+ drugs. While it lowers some prices, it avoids harsher mandates and expands direct-to-consumer sales, providing clarity and reducing regulatory risk.

  The deal removes a major overhang and shows Pfizer adapting to new pricing rules.

• ▼

  Patent lawsuits over COVID vaccine technology Arbutus and Roivant filed international patent suits against Pfizer over lipid nanoparticles in Comirnaty, seeking injunctions and damages. This adds legal costs and uncertainty, weighing on the stock.

  New litigation creates financial risk and potential disruption to a major product.

Based on 11 stories →

• ▲

  Pfizer pushes into next-gen obesity drugs with monthly dosing Pfizer aims to lead in next-generation obesity therapies with monthly dosing, advancing 10 phase 3 studies and targeting 2028 approval. This is a huge potential market, and success could add a major new growth engine, pushing the stock up.

  This is a key new positive development that could drive future revenue growth.

• ▲

  Pfizer seen as deep value with potential to double in 3-5 years Pfizer is viewed as a deep value opportunity, trading at a low P/E with a 6.5% dividend yield. Bulls point to the Seagen acquisition, GLP-1 pipeline, and over 20 Phase 3 trials as catalysts that could double the stock over three to five years.

  This highlights the investment case and potential upside, attracting value investors.

• ▼

  RFK Jr. ends COVID-19 drug EUAs, hitting Paxlovid sales HHS Secretary RFK Jr. terminated Emergency Use Authorizations for COVID-19 drugs, including Pfizer's Paxlovid. This reduces future sales of the treatment, weighing on revenue and the stock price.

  This is a new regulatory setback that directly impacts a Pfizer product.

• ▲

  Pfizer's strong balance sheet fuels acquisition hopes CEO Albert Bourla says Pfizer has a very big balance sheet and can pursue transformative acquisitions. The company could deepen its weight loss portfolio by acquiring Kailera Therapeutics, signaling financial strength and deal capacity.

  This shows Pfizer's ability to grow through M&A, which could boost future earnings.

Based on 8 stories →

• ▼

  CFO departure adds uncertainty Pfizer's CFO Dave Denton will leave on August 15, raising questions about financial leadership and the 2026 outlook. Shares fell on the news. A new CFO search adds near-term uncertainty, which can weigh on the stock until a permanent replacement is named.

  This is a new event that directly affects investor confidence in Pfizer's financial strategy.

• ▼

  Lung cancer drug fails Phase 3 trial Pfizer's sigvotatug vedotin did not significantly improve overall survival in a Phase 3 lung cancer trial. The drug came from the $43 billion Seagen acquisition. This setback raises doubts about the Seagen pipeline and pushed the stock down 7.3% on June 25.

  This is a major clinical failure that impacts Pfizer's oncology growth story and investor sentiment.

• ▲

  Obesity pipeline advances with monthly injection Pfizer is moving berobenatide into Phase 3 trials, aiming for 2028 approval. It's a monthly GLP-1 shot for obesity, a market expected to reach $120 billion by 2035. Positive Phase 2b data and over 20 planned studies give Pfizer a shot at a lucrative new market.

  This is a new pipeline update that could drive future revenue growth and offsets negative news.

• ▲

  IBRANCE approved for expanded breast cancer use The FDA approved IBRANCE for a new type of metastatic breast cancer, making it the first CDK4/6 inhibitor for both HR+ and HER2+ patients. This expands the market for an existing drug and helps offset pipeline setbacks.

  This is a new regulatory approval that strengthens Pfizer's oncology franchise and provides a revenue boost.

Based on 19 stories →